Further investigation is strongly encouraged in order to investigate whether the ability of leptin to stimulate proliferation of androgen-resistant prostate cancer cells might represent a novel diagnostic/prognostic factor by serial measurements of the serum leptin levels during the course of a certain therapy. This evidence concerns the gene LEP and prostate carcinoma.